![Michael Holdbrook](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Holdbrook
No open positions remaining
Profile
Michael Holdbrook worked as a Senior Director-Clinical Affairs & Biostatistics at Oculeve, Inc. from 2014 to 2017.
He then served as a Vice President at Experien Group LLC.
In 2018, he joined Tarsus Pharmaceuticals, Inc. as a Senior Vice President-Clinical Affairs, where he worked until 2023.
Mr. Holdbrook completed his undergraduate degree at the University of California San Diego.
Former positions of Michael Holdbrook
| Companies | Position | End |
|---|---|---|
| TARSUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2023-03-31 |
Oculeve, Inc.
 Oculeve, Inc. Medical SpecialtiesHealth Technology Develops devices for dry eye disease treatment | Corporate Officer/Principal | 2017-09-30 |
Experien Group LLC
 Experien Group LLC Miscellaneous Commercial ServicesCommercial Services Provides regulatory, quality and clinical consulting services | Corporate Officer/Principal | - |
Training of Michael Holdbrook
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
6
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Oculeve, Inc.
Oculeve, Inc. Medical SpecialtiesHealth Technology Develops devices for dry eye disease treatment | Health Technology |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Experien Group LLC
Experien Group LLC Miscellaneous Commercial ServicesCommercial Services Provides regulatory, quality and clinical consulting services | Commercial Services |
Tarsus Pharmaceuticals, Inc.
 Tarsus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapeutic drugs for blepharitis | Health Technology |
- Stock Market
- Insiders
- Michael Holdbrook
